07/09/2026
๐๐๐ค๐ข๐ง๐ ๐ ๐๐ญ๐ซ๐จ๐ง๐ ๐๐๐๐ฎ๐ญ ๐๐ญ ๐๐ง๐๐ข๐ ๐๐๐ ๐๐ฑ๐ฉ๐จ ๐๐๐ง๐ ๐๐ฅ๐ฎ๐ซ๐ฎ ๐๐๐๐ | ๐๐จ๐ญ๐ ๐๐ง ๐๐ก๐จ๐ฐ๐๐๐ฌ๐๐ฌ ๐๐จ๐ฆ๐ฉ๐ซ๐๐ก๐๐ง๐ฌ๐ข๐ฏ๐ ๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐๐ข๐๐ ๐ง๐จ๐ฌ๐ญ๐ข๐ ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ, ๐๐๐๐ฉ๐๐ง๐ข๐ง๐ ๐๐จ๐ฎ๐ญ๐ก ๐๐ฌ๐ข๐๐ง ๐๐๐ซ๐ค๐๐ญ ๐๐ซ๐๐ฌ๐๐ง๐๐
From September 5โ7, 2026, the 24th India Med Expo Bengaluru 2026 was held at the Bangalore International Exhibition Centre (BIEC) in Bengaluru, Karnataka. As one of Indiaโs premier B2B medical exhibitions, the event brought together healthcare professionals, hospital teams, laboratory experts, and decision-makers from across the country to explore the newest healthcare solutions.
Hotgen Biotech made a prominent appearance at Hall 2, Booth D96, showcasing its full range of immunodiagnostic solutions tailored for diverse clinical settings including hospital laboratories, primary healthcare facilities, emergency care, and public health applications. The booth attracted significant interest from local distributors and industry professionals, underscoring the innovation capabilities and regional adaptability of Chinese IVD brands in the Indian market.
๐๐จ๐ฆ๐ฉ๐ซ๐๐ก๐๐ง๐ฌ๐ข๐ฏ๐ ๐๐ซ๐จ๐๐ฎ๐๐ญ ๐๐จ๐ซ๐ญ๐๐จ๐ฅ๐ข๐จ ๐๐๐๐ซ๐๐ฌ๐ฌ๐ข๐ง๐ ๐๐๐ ๐ข๐จ๐ง๐๐ฅ ๐๐๐๐๐ฌ
At the exhibition, Hotgen highlighted a broad selection of immunodiagnostic products designed for the Indian market, including chemiluminescence immunoassay platforms (MQ60 series and C2100 series), the UPT2800 rapid POCT system, the TB-IGRA tuberculosis infection detection assay, as well as colloidal gold and ELISA reagent products. This portfolio spans a wide spectrum of clinical applicationsโfrom point-of-care screening in primary settings to high-throughput testing in central laboratories.
The chemiluminescence product line, combining compact benchtop systems with fully automated high-throughput analyzers, meets the testing needs of healthcare facilities of varying sizes. The POCT system, distinguished by its speed and ease of use, is particularly suited for emergency response and remote-area screening. The TB-IGRA assay directly addresses Indiaโs high tuberculosis burden, delivering clear clinical utility in infection screening and auxiliary diagnosis. Meanwhile, the conventional reagent offerings, with their cost-effectiveness and convenient storage and transport, present a practical solution for grassroots healthcare facilities.
๐๐ก๐๐ง๐ง๐๐ฅ ๐๐ง๐ ๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐ง๐ ๐๐จ๐๐๐ฅ ๐๐๐ซ๐ญ๐ง๐๐ซ๐ฌ๐ก๐ข๐ฉ ๐๐ฎ๐ข๐ฅ๐๐ข๐ง๐
Leveraging the India Med Expo platformโa key gathering for the countryโs healthcare industryโHotgen engaged in in-depth one-on-one discussions with distributors and industry professionals from across India, gaining firsthand insights into local market priorities regarding product performance, regulatory registration status, pricing structures, and after-sales support. Multiple cooperation intentions were established during these conversations, laying a solid foundation for subsequent channel development across the region.
๐๐๐ ๐ข๐จ๐ง๐๐ฅ ๐
๐จ๐๐ฎ๐ฌ, ๐๐ญ๐๐๐๐ฒ ๐๐๐ฏ๐๐ง๐๐๐ฆ๐๐ง๐ญ ๐จ๐ ๐๐ง๐๐ข๐ ๐๐ญ๐ซ๐๐ญ๐๐ ๐ฒ
As one of the most promising healthcare markets in South Asia, India remains a strategic priority for Hotgenโs global expansion. The Company will continue to deepen collaboration with regional industry organizations and exhibition platforms, accelerate regulatory registration of its products in India, and work toward establishing a localized after-sales support framework to better serve the market with solutions that are closely attuned to local needs.
Looking ahead, Hotgen remains committed to strengthening its regional presence through innovative diagnostic technologies and localized partnership models, contributing to the advancement of healthcare across South Asia.
๐๐ฏ๐๐ง๐ญ ๐๐ง๐๐ฉ๐ฌ๐ก๐จ๐ญ
โข๐๐ฏ๐๐ง๐ญ: India Med Expo Bengaluru 2026 (24th Edition)
โข๐๐๐ญ๐: September 5โ7, 2026
โข๐๐๐ง๐ฎ๐: Hall 2, Booth D96, Bangalore International Exhibition Centre (BIEC), Bengaluru, Karnataka, India
